PortfoliosLab logoPortfoliosLab logo
MREO vs. ONCT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MREO vs. ONCT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mereo BioPharma Group plc (MREO) and Oncternal Therapeutics, Inc. (ONCT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


MREO

1D
10.27%
1M
30.54%
YTD
-18.55%
6M
-80.61%
1Y
-86.69%
3Y*
-31.59%
5Y*
-37.64%
10Y*

ONCT

1D
0.00%
1M
0.00%
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

MREO vs. ONCT - Yearly Performance Comparison


Correlation

The correlation between MREO and ONCT is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (All Time)
Calculated using the full available price history since Feb 9, 2026

0.07

Fundamentals

Total Revenue (TTM)

MREO:

$500.00K

ONCT:

$1.67M

Gross Profit (TTM)

MREO:

$366.00K

ONCT:

-$16.96M

EBITDA (TTM)

MREO:

-$39.61M

ONCT:

-$17.87M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MREO vs. ONCT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MREO
MREO Risk / Return Rank: 1414
Overall Rank
MREO Sharpe Ratio Rank: 1313
Sharpe Ratio Rank
MREO Sortino Ratio Rank: 2424
Sortino Ratio Rank
MREO Omega Ratio Rank: 2121
Omega Ratio Rank
MREO Calmar Ratio Rank: 55
Calmar Ratio Rank
MREO Martin Ratio Rank: 99
Martin Ratio Rank

ONCT
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MREO vs. ONCT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Mereo BioPharma Group plc (MREO) and Oncternal Therapeutics, Inc. (ONCT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


MREOONCTDifference

Sharpe ratio

Return per unit of total volatility

-0.65

Sortino ratio

Return per unit of downside risk

-0.25

Omega ratio

Gain probability vs. loss probability

0.95

Calmar ratio

Return relative to maximum drawdown

-0.92

Martin ratio

Return relative to average drawdown

-1.35

MREO vs. ONCT - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


MREOONCTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.65

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.38

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.30

1.67

-1.97

Drawdowns

MREO vs. ONCT - Drawdown Comparison

The maximum MREO drawdown since its inception was -96.35%, which is greater than ONCT's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for MREO and ONCT.


Loading charts...

Drawdown Indicators


MREOONCTDifference

Max Drawdown

Largest peak-to-trough decline

-96.35%

0.00%

-96.35%

Max Drawdown (1Y)

Largest decline over 1 year

-91.93%

Max Drawdown (3Y)

Largest decline over 3 years

-95.13%

Max Drawdown (5Y)

Largest decline over 5 years

-95.13%

Current Drawdown

Current decline from peak

-94.78%

0.00%

-94.78%

Average Drawdown

Average peak-to-trough decline

-65.88%

0.00%

-65.88%

Ulcer Index

Depth and duration of drawdowns from previous peaks

62.41%

Volatility

MREO vs. ONCT - Volatility Comparison


Loading charts...

Volatility by Period


MREOONCTDifference

Volatility (1M)

Calculated over the trailing 1-month period

37.15%

Volatility (6M)

Calculated over the trailing 6-month period

224.43%

Volatility (1Y)

Calculated over the trailing 1-year period

135.47%

0.00%

+135.47%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

100.56%

0.00%

+100.56%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

113.69%

0.00%

+113.69%

Dividends

MREO vs. ONCT - Dividend Comparison

Neither MREO nor ONCT has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

MREO vs. ONCT - Financials Comparison

This section allows you to compare key financial metrics between Mereo BioPharma Group plc and Oncternal Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M2022202320242025202600
(MREO) Total Revenue
(ONCT) Total Revenue
Values in USD except per share items

Frequently Asked Questions


MREO and ONCT have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for MREO and ONCT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer